TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7820356

Group type: EXPERIMENTAL
Intervention: Imaginal exposure followed by live exposure (Group 1)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Live exposure followed by imaginal exposure (Group 2)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Live exposure (as compared to imaginal exposure)
Number of subjects: 14
Study: 2898536

Group type: EXPERIMENTAL
Intervention: Combined-modality therapy (chemotherapy plus radiotherapy)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Chemotherapy alone (SMF: streptozocin, mitomycin, and 5-fluorouracil)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Combined-modality therapy
Number of subjects: 43

Group type: COMPARATOR
Intervention: Chemotherapy alone (SMF)
Number of subjects: 43
Study: 31397771

Group type: EXPERIMENTAL
Intervention: Tai Chi (TC)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Resistance Band (RB) exercise
Number of subjects: 70

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 70
Study: 28557299

Group type: EXPERIMENTAL
Intervention: Internet-based guided self-help with up to 3 h of therapist assistance
Number of subjects: 42

Group type: COMPARATOR
Intervention: Delayed treatment control group
Number of subjects: 42
Study: 25427944

Group type: EXPERIMENTAL
Intervention: Slow-release oral morphine
Number of subjects: 157

Group type: COMPARATOR
Intervention: Methadone
Number of subjects: 157
Study: 23865955

Group type: EXPERIMENTAL
Intervention: Proton pump inhibitors (PPIs)
Number of subjects: 184480
Study: 21639810

Group type: EXPERIMENTAL
Intervention: Ipilimumab (10 mg per kilogram) plus dacarbazine (850 mg per square meter)
Number of subjects: 502

Group type: COMPARATOR
Intervention: Dacarbazine (850 mg per square meter) plus placebo
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: Ipilimumab plus dacarbazine
Number of subjects: 502

Group type: COMPARATOR
Intervention: Dacarbazine plus placebo
Number of subjects: 502
Study: 20048532

Group type: EXPERIMENTAL
Intervention: Whole body vibration exercises (frequency 35 Hz, intensity high, amplitude 4 mm) during dynamic (squatting, calf raises) and static (standing) exercises for 3 minutes
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Calf raises with whole body vibration
Number of subjects: 20

Group type: COMPARATOR
Intervention: Calf raises without whole body vibration
Number of subjects: 20
Study: 16672833

Group type: EXPERIMENTAL
Intervention: Modifiable Activity Questionnaire (MAQ; past year)
Number of subjects: 3234

Group type: EXPERIMENTAL
Intervention: Low‐Level Physical Activity Recall (LOPAR; past 7 d)
Number of subjects: 3234

Group type: EXPERIMENTAL
Intervention: Third National Health and Nutrition Examination Survey (NHANES III; past month)
Number of subjects: 3234
Study: 14748941

Group type: EXPERIMENTAL
Intervention: Antioxidant mixture (Se 150 microg, retinyl acetate mg, ascorbic acid 120 mg, alpha‐tocopheryl succinate 20 mg)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Antioxidant mixture
Number of subjects: 17
Study: 11295719

Group type: EXPERIMENTAL
Intervention: Oral diazepam
Number of subjects: 406

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 406
Study: 9649986

Group type: EXPERIMENTAL
Intervention: Granisetron 20 micrograms kg‐1
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Granisetron 40 micrograms kg‐1
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Granisetron 80 micrograms kg‐1
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 120
Study: 8198414

Group type: EXPERIMENTAL
Intervention: Ethamsylate (165 infants received the drug)
Number of subjects: 334

Group type: COMPARATOR
Intervention: Control (169 infants, only 1 received ethamsylate)
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Ethamsylate
Number of subjects: 334

Group type: COMPARATOR
Intervention: Control
Number of subjects: 334
Study: 2830918

Group type: EXPERIMENTAL
Intervention: 4-aminopyridine (4-AP) 2.5 mg b.i.d.
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 4-aminopyridine (4-AP) 5 mg b.i.d.
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 4-aminopyridine (4-AP) 10 mg b.i.d.
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 30187572

Group type: EXPERIMENTAL
Intervention: Topical administration of 2% lidocaine solution 20mL (LID, n=64)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Normal saline 20mL (control, n=64)
Number of subjects: 128
Study: 29364340

Group type: EXPERIMENTAL
Intervention: Probiotic (Lactobacillus rhamnosus SP1)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Antibiotic (Azithromycin 500mg)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 26847966

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) therapy
Number of subjects: 357
Study: 25179975

Group type: EXPERIMENTAL
Intervention: Delayed surgical closure following a vacuum‐assisted closure system (VAC)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Primary surgical closure (PSC)
Number of subjects: 58
Study: 22549286

Group type: EXPERIMENTAL
Intervention: Almorexant 400 mg
Number of subjects: 161

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 161
Study: 20626422

Group type: EXPERIMENTAL
Intervention: Conventionally placed submerged implants (Group 1)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Early-placed submerged implants (Group 2)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Group 1 implants
Number of subjects: 46

Group type: COMPARATOR
Intervention: Group 2 implants
Number of subjects: 46

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 46
Study: 17141318

Group type: EXPERIMENTAL
Intervention: Baseline intraocular pressure (IOP) measurements including mean diurnal, peak, trough, IOP range (peak - trough), and standard deviation (SD) of IOP.
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Patients with unilateral VF loss (n = 53)
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Patients with bilateral VF loss (n = 137)
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Cross-classified contingency tables analysis
Number of subjects: 190
Study: 15618783

Group type: EXPERIMENTAL
Intervention: Propofol (n = 6)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Thiopental (n = 4)
Number of subjects: 10
Study: 11996262

Group type: COMPARATOR
Intervention: Conventional technique (group C) - the vein was stripped, distended, and stored in saline
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Intermediate technique (group I) - the vein was stripped, local application of papaverine was used instead of distention, and the vessel was then stored in heparinized blood
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: No-touch technique (group NT) - the vein was harvested with surrounding tissue, not distended, and stored in heparinized blood
Number of subjects: 156
Study: 10404741

Group type: EXPERIMENTAL
Intervention: Enzyme-linked immunosorbent assay (ELISA) for acidic fibroblast growth factor (aFGF)
Number of subjects: 0
Study: 7733123

Group type: EXPERIMENTAL
Intervention: SCT 50 IU/d
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: SCT 200 IU/d
Number of subjects: 251

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 251
Study: 1972494

Group type: EXPERIMENTAL
Intervention: Presence of axillary lymph node micrometastases
Number of subjects: 921

Group type: COMPARATOR
Intervention: Negative nodes on serial sectioning
Number of subjects: 921
Study: 7188714

Group type: EXPERIMENTAL
Intervention: Ampicillin
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 31107344

Group type: EXPERIMENTAL
Intervention: Subcutaneous immunoglobulin (SCIG), a 20% solution stabilized with L‐proline, FDA-approved for CIDP maintenance therapy.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 28370991

Group type: EXPERIMENTAL
Intervention: Polyethylene cap (NeoCap)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Cotton cap (Control)
Number of subjects: 80
Study: 24786301

Group type: EXPERIMENTAL
Intervention: Copeptin group (negative troponin and copeptin values at admission)
Number of subjects: 902

Group type: COMPARATOR
Intervention: Standard care group
Number of subjects: 902

Group type: COMPARATOR
Intervention: Standard care group (per protocol analysis)
Number of subjects: 902

Group type: EXPERIMENTAL
Intervention: Copeptin group (per protocol analysis)
Number of subjects: 902
Study: 24215419

Group type: EXPERIMENTAL
Intervention: Paroxysmal Atrial Fibrillation (AF) group
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group (without paroxysmal AF)
Number of subjects: 51
Study: 22270266

Group type: EXPERIMENTAL
Intervention: Race-discordant relationships (black patient, white provider) with collaborative communication
Number of subjects: 597

Group type: EXPERIMENTAL
Intervention: Race-discordant relationships (black patient, white provider) with less collaborative communication
Number of subjects: 597

Group type: COMPARATOR
Intervention: Race-concordant relationships (black patient, black provider)
Number of subjects: 597
Study: 19403902

Group type: EXPERIMENTAL
Intervention: T12PR24 group (telaprevir 1250 mg on day 1 and 750 mg every 8 hours for 12 weeks, plus peginterferon alfa‐2a and ribavirin for 24 weeks)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: T12PR48 group (telaprevir for 12 weeks, plus peginterferon alfa‐2a and ribavirin for 48 weeks)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: T12PR12 group (telaprevir for 12 weeks, plus peginterferon alfa‐2a and ribavirin for 12 weeks)
Number of subjects: 250

Group type: COMPARATOR
Intervention: PR48 group (peginterferon alfa‐2a and ribavirin for 48 weeks, plus telaprevir-matched placebo for 12 weeks)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: All telaprevir groups
Number of subjects: 250
Study: 17848497

Group type: EXPERIMENTAL
Intervention: Fish oil
Number of subjects: 232

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 232
Study: 15086491

Group type: EXPERIMENTAL
Intervention: Vitamin E-coated dialyzer (VE)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Cellulosic membrane (CM)
Number of subjects: 10
Study: 11116287

Group type: EXPERIMENTAL
Intervention: Vatanidipine
Number of subjects: 0
Study: 9709043

Group type: EXPERIMENTAL
Intervention: Nonoxynol 9 film
Number of subjects: 1292

Group type: COMPARATOR
Intervention: Placebo film
Number of subjects: 1292
Study: 8011392

Group type: EXPERIMENTAL
Intervention: 0.1 mmol/kg gadodiamide injection
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: 0.3 mmol/kg gadodiamide injection
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Overall diagnostic utility of gadodiamide injection
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Safety profile of gadodiamide injection
Number of subjects: 49
Study: 1954210

Group type: EXPERIMENTAL
Intervention: Blue-green laser
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Yellow laser
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Orange laser
Number of subjects: 25
Study: 209881

Group type: COMPARATOR
Intervention: CTX (Cytoxan)
Number of subjects: 37

Group type: COMPARATOR
Intervention: COMF (CTX, oncovin, methotrexate and 5-FU)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: AMCOF (adriamycin, methotrexate, CTX, oncovin and 5-FU)
Number of subjects: 37

Group type: COMPARATOR
Intervention: CTX (for small cell carcinoma)
Number of subjects: 37

Group type: COMPARATOR
Intervention: COMF (for small cell carcinoma)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: AMCOF (for small cell carcinoma)
Number of subjects: 37

Group type: COMPARATOR
Intervention: CTX (for adenocarcinoma or epidermoid carcinoma)
Number of subjects: 37

Group type: COMPARATOR
Intervention: COMF (for adenocarcinoma or epidermoid carcinoma)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: AMCOF (for adenocarcinoma or epidermoid carcinoma)
Number of subjects: 37
Study: 27778151

Group type: EXPERIMENTAL
Intervention: Magnesium supplementation
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Low dietary intake of magnesium (<250 mg/day)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: High dietary intake of magnesium (>250 mg/day)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Controlled metabolic unit balance studies
Number of subjects: 70
Study: 25055838

Group type: EXPERIMENTAL
Intervention: mBATRAC (bilateral upper-limb training)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: mCIMT (unilateral upper-limb training)
Number of subjects: 60

Group type: COMPARATOR
Intervention: DMCT (dose-matched control treatment)
Number of subjects: 60
Study: 24210600

Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure (CPAP) therapy for 12 weeks
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure (CPAP) therapy
Number of subjects: 53
Study: 22101701

Group type: EXPERIMENTAL
Intervention: SGIP acupuncture therapy
Number of subjects: 63

Group type: COMPARATOR
Intervention: Pinaverium bromide (control)
Number of subjects: 63
Study: 19289935

Group type: EXPERIMENTAL
Intervention: Multimedia flip chart
Number of subjects: 35
Study: 18600327

Group type: EXPERIMENTAL
Intervention: Aerobic exercise in sea water
Number of subjects: 46

Group type: COMPARATOR
Intervention: Aerobic exercise in water pool
Number of subjects: 46
Study: 15244227

Group type: EXPERIMENTAL
Intervention: Skin-to-skin contact (SSC) from birth
Number of subjects: 34

Group type: COMPARATOR
Intervention: Incubator care
Number of subjects: 34
Study: 11602221

Group type: EXPERIMENTAL
Intervention: Propranolol (beta 1 and beta 2 receptor antagonist)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Isoproterenol
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo infusion before an injection of placebo
Number of subjects: 27
Study: 9595523

Group type: EXPERIMENTAL
Intervention: Captopril treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 0
Study: 8082098

Group type: EXPERIMENTAL
Intervention: Cisplatin as a radiosensitizer with an induction phase of 4500 cGy and two cycles of cisplatin followed by radical surgery (Group A)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Cisplatin as a radiosensitizer with an induction phase of 4500 cGy and two cycles of cisplatin followed by radical radiotherapy (Group B)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Cisplatin as a radiosensitizer with an induction phase of 4500 cGy and two cycles of cisplatin followed by radical surgery or radiotherapy
Number of subjects: 68
Study: 2688428

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Number of subjects: 213

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 213
Study: 766118

Group type: EXPERIMENTAL
Intervention: Sotalol
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study: 11903210

Group type: EXPERIMENTAL
Intervention: Active management of labor (n = 320)
Number of subjects: 651

Group type: COMPARATOR
Intervention: Routine care (n = 331)
Number of subjects: 651
Study: 31216125

Group type: EXPERIMENTAL
Intervention: Denosumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Risedronate
Number of subjects: 0
Study: 29873956

Group type: EXPERIMENTAL
Intervention: MIN‐101 32 mg
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: MIN‐101 64 mg
Number of subjects: 244

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 244
Study: 26925955

Group type: EXPERIMENTAL
Intervention: VR balance training program using the CAREN system for 6 weeks, 2 sessions per week, 30 minutes each session.
Number of subjects: 32

Group type: COMPARATOR
Intervention: Conventional balance exercise group for 6 weeks, 2 sessions per week, 30 minutes each session.
Number of subjects: 32
Study: 25281300

Group type: EXPERIMENTAL
Intervention: Home-based breastfeeding support
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Home-based breastfeeding support plus access to a community-based breastfeeding drop-in centre
Number of subjects: 450

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 450
Study: 22301931

Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion (ATD)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 19930762

Group type: EXPERIMENTAL
Intervention: HFrD (hypercaloric diet enriched with fructose, 3.5 g fructose/kg fat‐free mass per day, +35% energy intake)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: HGlcD (hypercaloric diet enriched with glucose, 3.5 g glucose/kg fat‐free mass per day, +35% energy intake)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Weight maintenance control diet
Number of subjects: 11
Study: 17350525

Group type: EXPERIMENTAL
Intervention: Levobupivacaine 0.25% (19-mL bolus) followed by levobupivacaine 0.1% infusion
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Fentanyl 50 microg (19-mL bolus) followed by levobupivacaine 0.05% with fentanyl 4 microg/mL infusion
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Clonidine 150 microg (19-mL bolus) followed by levobupivacaine 0.05% with clonidine 3 microg/mL infusion
Number of subjects: 38
Study: 15716984

Group type: EXPERIMENTAL
Intervention: Infection control program
Number of subjects: 0
Study: 11929640

Group type: EXPERIMENTAL
Intervention: Oral contraceptives (OCs)
Number of subjects: 987

Group type: EXPERIMENTAL
Intervention: Second-generation progestins (levonorgestrel or norgestimate)
Number of subjects: 987

Group type: EXPERIMENTAL
Intervention: Third-generation progestins (desogestrel or gestodene)
Number of subjects: 987

Group type: EXPERIMENTAL
Intervention: Oral contraceptives with 20 microg estrogen
Number of subjects: 987

Group type: EXPERIMENTAL
Intervention: Oral contraceptives with 50 microg estrogen
Number of subjects: 987

Group type: EXPERIMENTAL
Intervention: Third/second-generation OCs
Number of subjects: 987
Study: 11229219

Group type: EXPERIMENTAL
Intervention: Zinc sulphate (660 mg) for 6 weeks (Group‐‐IIB)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo for 6 weeks (Group‐‐IIA)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Healthy controls (Group‐‐I)
Number of subjects: 50
Study: 7649958

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) 0.3 mg/kg
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) 0.6 mg/kg
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) 0.9 mg/kg
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) (all dosages)
Number of subjects: 17
Study: 2627869

Group type: EXPERIMENTAL
Intervention: Social Learning Intervention (SLI) with role modeling
Number of subjects: 34

Group type: COMPARATOR
Intervention: Traditional diabetes instruction (Control)
Number of subjects: 34
Study: 1091138

Group type: EXPERIMENTAL
Intervention: Complete dietary supplement consisting of a beef serum hydrolysate, a glucose polymer, and medium‐chain triglycerides
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (patients who did not receive the supplement)
Number of subjects: 15
Study: 31328599

Group type: EXPERIMENTAL
Intervention: Experimental group received a training course comprising of 20 hours over 5 weeks.
Number of subjects: 28

Group type: COMPARATOR
Intervention: Conventional training group.
Number of subjects: 28
Study: 28549048

Group type: EXPERIMENTAL
Intervention: Disposable underpads
Number of subjects: 462

Group type: COMPARATOR
Intervention: Reusable underpads
Number of subjects: 462
Study: 26786080

Group type: EXPERIMENTAL
Intervention: Mirror Therapy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Classic Sensory Re-education (Control)
Number of subjects: 20
Study: 24667751

Group type: EXPERIMENTAL
Intervention: Glucose (200 kcal/250 ml)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Sucrose (200 kcal/250 ml)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: High-fructose corn syrup (HFCS) (200 kcal/250 ml)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: HFCS (200 kcal/250 ml)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Sucralose (non-caloric control)
Number of subjects: 15
Study: 21900886

Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 19164774

Group type: EXPERIMENTAL
Intervention: 6-month high-intensity exercise program
Number of subjects: 49

Group type: COMPARATOR
Intervention: Inactive control period
Number of subjects: 49
Study: 17878516

Group type: EXPERIMENTAL
Intervention: DNA microarrays and tissue microarrays for biomarker validation
Number of subjects: 0
Study: 15277595

Group type: EXPERIMENTAL
Intervention: Chewing visco-elastic model foods of different hardness
Number of subjects: 67
Study: 11354406

Group type: EXPERIMENTAL
Intervention: Shunt with Delta valves
Number of subjects: 12

Group type: COMPARATOR
Intervention: Shunt with Hakim shunts
Number of subjects: 12
Study: 9164415

Group type: EXPERIMENTAL
Intervention: Delavirdine mesylate (200 mg every 8 hours, 300 mg every 8 hours, 400 mg every 8 hours)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control group (300 mg every 8 hours)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Delavirdine mesylate (all doses)
Number of subjects: 8
Study: 7965930

Group type: EXPERIMENTAL
Intervention: Brief, structured pain management program (three-session program)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Matched controls (no specific intervention mentioned)
Number of subjects: 26
Study: 2885638

Group type: COMPARATOR
Intervention: Whole marrow (group A)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Marrow depleted of T cells by treatment with monoclonal antibodies (anti CD4‐CD5‐CD8, group B)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Marrow depleted of T cells by treatment with monoclonal antibodies (anti CD2‐CD5‐CD7, group C)
Number of subjects: 71
Study: 31994173

Group type: EXPERIMENTAL
Intervention: Multimedia module
Number of subjects: 75

Group type: COMPARATOR
Intervention: Written information
Number of subjects: 75
Study: 29412335

Group type: EXPERIMENTAL
Intervention: Art therapy (20 weekly sessions, 90 min/session)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 56
Study: 28257246

Group type: EXPERIMENTAL
Intervention: Attention training
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control program
Number of subjects: 76
Study: 26394351

Group type: EXPERIMENTAL
Intervention: Autograft
Number of subjects: 15

Group type: COMPARATOR
Intervention: Allograft
Number of subjects: 15
Study: 23673096

Group type: EXPERIMENTAL
Intervention: Acute normovolemic hemodilution (ANH)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Acute hypervolemic hemodilution (AHH)
Number of subjects: 40